Company

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals has 23 drugs tracked on RxWires: 1 approved, 1 in Phase 3, 8 in Phase 2, 8 in Phase 1/2, 5 in Phase 1.

Pipeline

Drug	Phase	Indication
REDEMPLO	Approved
Zodasiran	Phase 3	Homozygous Familial Hypercholesterolemia
ARC-520 Injection	Phase 2	Chronic Hepatitis B
ARO-APOC3	Phase 2	Severe Hypertriglyceridemia
ARO-ANG 3 Injection	Phase 2	Homozygous Familial Hypercholesterolemia
ARO-RAGE	Phase 2	Asthma
Fazisiran Injection	Phase 2	Alpha 1-Antitrypsin Deficiency
ARC-AAT Injection	Phase 2	Alpha-1 Antitrypsin Deficiency
ARO-INHBE	Phase 2	Metabolic Dysfunction-Associated Steatohepatitis
ARO-AAT	Phase 2	Alpha 1-Antitrypsin Deficiency
ARO-C3	Phase 1/2	C3 Glomerulopathy
ARO-ENaC	Phase 1/2	Cystic Fibrosis, Pulmonary
ARO-HBV	Phase 1/2	Hepatitis B
ARO-MAPT-SC	Phase 1/2	Alzheimer Disease
ARO-MUC5AC	Phase 1/2	Asthma
ARO-ALK7	Phase 1/2	Obesity
ARO-DIMERPA	Phase 1/2	Hyperlipidemia; Mixed
ARO-MMP7 Inhalation Solution	Phase 1/2	Idiopathic Pulmonary Fibrosis
ARO-CFB	Phase 1	IgA Nephropathy
ARO-033	Phase 1	Age-related Macular Degeneration
ARO-SOD1 Injection	Phase 1	Amyotrophic Lateral Sclerosis
ARO-ATXN2 Injection	Phase 1	Spinocerebellar Ataxia Type 2
ARO-ANG3	Phase 1	Dyslipidemias

Follow Arrowhead Pharmaceuticals on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.

Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.